Market Cap
$998.5M
PCRX
Pacira BioSciences, Inc.
$25.02 ▲ +0.04%
Prev close $25.01Market cap$998.5M
ConsensusBuy
12-mo target$30.00 (+19.9%)
▲ Bullish
Analyst conviction 7/10
Insider Selling Cluster (2 insiders)High Impact Filing (7/10)21 New Institutional Positions15 Institutional Exits Biotech & Drug Discovery
Snapshot
The big-picture read on PCRX right now — valuation, ownership and activity at a glance.
Cap Size
Small Cap
Analyst Consensus
Buy (69%)
Inst. Holders
50 funds
Inst. Value
$860.4M
Inst. Activity
21 buys / 15 sells
Insider Activity
$0.00 buy / $1.5M sell
Insider Net $
-$1.5M
SEC Reports
12
Press Releases
4
Price chart 30d -5.9%
Daily candles (open–high–low–close) with volume. Green = up day, red = down day.
No data for this timeframe.
Vol
Recent activity
The latest filings, insider trades, analyst actions, press and options flow — newest first.
Sep 10, 2026 clinical_trial_readout
T-90d Trial Readout: ZILRETTA (Phase 3)
Trial: ZILRETTA in Subjects With Shoulder Osteoarthritis Sponsor: Pacira Pharmaceuticals, Inc Phase:
Aug 17, 2026 Insider
Aug 6, 2026 Press SLONIN JONATHAN sold 3,040 shares
Chief Medical Officer @ $23.23 ($70.6K)
Pacira BioSciences reported positive two-year Phase 1 data for PCRX-201, a gene therapy for knee osteoarthritis, publish
Impact 6/10
Pacira BioSciences announced it will report Q2 2026 financial results after market close on August 4, 2026, followed by
PRESS-RELEASE — Impact 1/10
Pacira BioSciences has agreed to sell its iovera handheld cryoanalgesia device business to Zimmer Biomet for up to $140M
8-K — Impact 7/10
Jun 30, 2026 Inst.
UBS Group AG — ADD
920,217 shares ($23.3M)
Jun 30, 2026 Inst.
Jun 13, 2026 SEC Jefferies Financial Group Inc. — ADD
370,092 shares ($9.4M)
Pacira BioSciences saw two insider sales totaling $372K over a week, including the Chief Administrative Officer and SVP
CLUSTER — Impact 3/10
Analyst ratings buy % +0.0%
How Wall Street rates the stock today, and the latest firm-by-firm actions.
69% rate it Buy or better · 13 analysts
Recent analyst actions
| Date | Firm | Action | Rating | Firm rating |
|---|---|---|---|---|
| Sep 23, 2026 | Oppenheimer | INITIATE | Outperform | 52% |
| Sep 9, 2026 | Leerink Partners | INITIATE | Market Perform | 49% |
| Aug 5, 2026 | RBC Capital | MAINTAIN | Sector Perform | 55% |
| Aug 5, 2026 | Needham | MAINTAIN | Buy | 50% |
| Jul 1, 2026 | HC Wainwright & Co. | REITERATE | Buy | 43% |
| May 1, 2026 | RBC Capital | MAINTAIN | Sector Perform | 55% |
| May 1, 2026 | Needham | MAINTAIN | Buy | 50% |
Monthly consensus history
| Period | Str. Buy | Buy | Hold | Sell | Str. Sell | Buy % | Distribution |
|---|---|---|---|---|---|---|---|
| Sep 1, 2026 | 3 | 6 | 3 | 1 | 0 | 69% | |
| Aug 1, 2026 | 3 | 5 | 3 | 1 | 0 | 67% | |
| Jul 1, 2026 | 3 | 5 | 3 | 1 | 0 | 67% | |
| Jun 1, 2026 | 3 | 6 | 3 | 1 | 0 | 69% | |
| May 1, 2026 | 3 | 6 | 3 | 1 | 0 | 69% | |
| Apr 1, 2026 | 3 | 6 | 3 | 1 | 0 | 69% | |
| Mar 1, 2026 | 3 | 6 | 3 | 1 | 0 | 69% | |
| Feb 1, 2026 | 3 | 6 | 3 | 1 | 0 | 69% |
Price targets
Where 9 covering analysts think PCRX trades over the next 12 months.
$30.00 +19.9% upside Buy
Current$25.02 Low$23.00 Median$30.00 High$38.00 9 analysts
$23.00$38.00
Analyst rating Buy· 2.1/5 as of Oct 2, 2026
Reports & filings
AI-scored summaries of recent SEC filings and press releases, with sentiment and impact.
12 SEC filing reports analyzed · 1 bullish, 0 bearish, 5 mixed, 6 neutral · avg impact 4.5/10.Plus 4 press releases.
NEUTRALPRESS-RELEASE1/10
Pacira BioSciences announced it will report Q2 2026 financial results after market close on August 4
Jul 22, 2026
BULLISH8-K7/10
Pacira BioSciences has agreed to sell its iovera handheld cryoanalgesia device business to Zimmer Bi
Jun 30, 2026
NEUTRALCLUSTER3/10
Pacira BioSciences saw two insider sales totaling $372K over a week, including the Chief Administrat
Jun 13, 2026
MIXEDDEFA14A6/10
Pacira BioSciences issued a DEFA14A press release reminding stockholders to vote FOR management's th
Jun 5, 2026
Upcoming & catalyst events
Scheduled dates plus disclosed catalysts — earnings, dividends, enforcement, FDA and clinical-trial events. Colored dot = impact.
Sep 10, 2026
Clinical Trial
ZILRETTA in Subjects With Shoulder Osteoarthritis
Phase Phase 3 — ACTIVE_NOT_RECRUITING
Sep 10, 2026
clinical_trial_readout
T-90d Trial Readout: ZILRETTA (Phase 3)
Trial: ZILRETTA in Subjects With Shoulder Osteoarthritis Sponsor: Pacira Pharmaceuticals, Inc Phase: Phase 3 | Status: ACTIVE_NOT_RECRUITING Condition
Sep 2, 2026
clinical_trial_readout
T-90d Trial Readout: ZILRETTA (Phase 3)
Trial: ZILRETTA in Subjects With Shoulder Osteoarthritis Sponsor: Pacira Pharmaceuticals, Inc Phase: Phase 3 | Status: ACTIVE_NOT_RECRUITING Condition
Aug 7, 2026
other
Pacira BioSciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
BRISBANE, Calif., Aug. 07, 2026 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX), the industry leader in the delivery of innovative, non-op
Aug 6, 2026
fda
Pacira BioSciences Announces Publication of Positive Two-Year Phase 1 Data For PCRX-201 in Annals of the Rheumatic Diseases
— A single locally administered intra-articular injection of PCRX-201 into the knee was well tolerated in patients with moderate-to-severe knee osteoa
Earnings estimates
Forecast earnings per share and revenue by period — and whether estimates are rising.
| Period | EPS Est. | Range | Growth | 30d Rev | Up/Dn | Revenue | # |
|---|---|---|---|---|---|---|---|
| Current Q | $0.73 | $0.50–$0.82 | 4.5% | +2.7% | 2↑ 3↓ | $0.2B | 9 |
| Next Q | $0.83 | $0.71–$0.93 | 45.4% | -1.5% | 2↑ 4↓ | $0.2B | 9 |
| Current FY | $2.89 | $2.72–$2.99 | 9.1% | +0.2% | 3↑ 3↓ | $0.8B | 9 |
| Next FY | $3.44 | $3.05–$3.94 | 19.1% | -0.2% | 0↑ 6↓ | $0.8B | 9 |
Current-quarter EPS estimate — revision history
| When | EPS estimate | Change vs now |
|---|---|---|
| Current | $0.732 | — |
| 7d ago | $0.724 | +0.007 |
| 30d ago | $0.712 | +0.020 |
| 60d ago | $0.759 | -0.027 |
| 90d ago | $0.759 | -0.027 |
Institutional ownership
Which big funds own PCRX (from quarterly 13F filings) and who is adding or trimming.
50 institutional holders with $860.4M total value (33,918,485 shares) as of 2026-Q2. Top holders: BlackRock,, VANGUARD, DIMENSIONAL. Net buying activity: 21 institutions added/increased vs 15 reduced.
Top holders — 2026-Q2
| Fund | Shares | Value | % Tracked | Last move |
|---|---|---|---|---|
| BlackRock, Inc. | 6,705,809 | $170.1M | 19.8% | — |
| VANGUARD PORTFOLIO MANAGEMENT LLC | 2,406,238 | $61.0M | 7.1% | — |
| DIMENSIONAL FUND ADVISORS LP | 2,103,245 | $53.4M | 6.2% | — |
| STATE STREET CORP | 2,059,977 | $52.3M | 6.1% | — |
| D. E. Shaw & Co., Inc. | 1,950,332 | $49.5M | 5.8% | — |
| RENAISSANCE TECHNOLOGIES LLC | 1,733,801 | $44.0M | 5.1% | — |
| VANGUARD CAPITAL MANAGEMENT LLC | 1,691,571 | $42.9M | 5.0% | — |
| GOLDMAN SACHS GROUP INC | 1,527,129 | $38.7M | 4.5% | — |
| GEODE CAPITAL MANAGEMENT, LLC | 1,158,693 | $29.4M | 3.4% | — |
| MORGAN STANLEY | 1,144,654 | $29.0M | 3.4% | — |
Recent position changes
| Fund | Action | Prev | Current | Change | Value |
|---|---|---|---|---|---|
| UBS Group AG | ADD | 562,040 | 920,217 | +63.7% | $23.3M |
| Jefferies Financial Group Inc. | ADD | 196,292 | 370,092 | +88.5% | $9.4M |
| JPMORGAN CHASE & CO | ADD | 240,369 | 346,697 | +44.2% | $8.7M |
| BANK OF AMERICA CORP /DE/ | ADD | 188,437 | 240,006 | +27.4% | $6.1M |
| MILLENNIUM MANAGEMENT LLC | DOUBLED | 57,031 | 235,163 | +312.3% | $6.0M |
| FMR LLC | DOUBLED | 93,481 | 217,001 | +132.1% | $5.5M |
| Empowered Funds, LLC | TRIM | 276,776 | 200,073 | -27.7% | $5.1M |
| CITADEL ADVISORS LLC | NEAR_EXIT | 797,281 | 162,164 | -79.7% | $4.1M |
| Universal- Beteiligungs- und Servicegesellschaft mbH | ADD | 80,017 | 140,434 | +75.5% | $3.6M |
| PRUDENTIAL FINANCIAL INC | TRIM | 182,873 | 79,703 | -56.4% | $2.0M |
Insider activity
Buying and selling by company executives and directors (SEC Form 4).
15 insiders, 45 transactions. Net -$1.5M — $0.00 bought, $1.5M sold.
| Date | Insider | Title | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Aug 17, 2026 | SLONIN JONATHAN | Chief Medical Officer | SELL | 3,040 | $23.23 | $70.6K |
| Jun 11, 2026 | RIKER LAUREN | Senior Vice President, Finance | SELL | 6,115 | $23.50 | $143.7K |
| Jun 10, 2026 | Brege Laura | Director | AWARD | 6,405 | — | — |
| Jun 10, 2026 | Froimson Mark | Director | AWARD | 6,405 | — | — |
| Jun 10, 2026 | CHRISTIE CHRISTOPHER | Director | AWARD | 6,405 | — | — |
| Jun 10, 2026 | WIGGANS THOMAS G | Director | AWARD | 32,675 | — | — |
| Jun 10, 2026 | CHRISTIE CHRISTOPHER | Director | AWARD | 10,891 | — | — |
| Jun 10, 2026 | YANG MICHAEL J. | Director | AWARD | 6,405 | — | — |
| Jun 10, 2026 | Young Alethia | Director | AWARD | 6,405 | — | — |
| Jun 10, 2026 | YANG MICHAEL J. | Director | AWARD | 10,891 | — | — |
Short interest & halts
FINRA semi-monthly short positions, Reg SHO threshold status, and recent trading halts for PCRX.
Shares short
7,561,153
Settlement Sep 15, 2026
Change vs prior
+3.2%
Semi-monthly cycle
Days to cover
13.0
At avg daily volume
Of shares outstanding
≈19.0%
Estimate — not % of float
All PCRX filing & press-release reports (16)
- PRESS-RELEASE reportAug 6, 2026
- PRESS-RELEASE reportJul 22, 2026
- 8-K reportJun 30, 2026
- CLUSTER reportJun 13, 2026
- DEFA14A reportJun 5, 2026
- 144 reportJun 4, 2026
- DEFA14A reportJun 1, 2026
- DEFA14A reportMay 27, 2026
- DEFA14A reportMay 26, 2026
- DEFA14A reportMay 20, 2026
- PRESS-RELEASE reportMay 20, 2026
- 8-K reportApr 30, 2026
- PREC14A reportApr 17, 2026
- PRESS-RELEASE reportApr 13, 2026
- DEFA14A reportMar 11, 2026
- PRESS-RELEASE reportMar 11, 2026